ABSTRACT
BACKGROUND AND OBJECTIVE: Data on radiofrequency ablation (RFA) of liver metastasis has not been uniform. The goal of this study was to determine medium-term success of CT-guided RFA of liver metastases from colorectal cancer. PATIENTS AND METHODS: 43 consecutive patients (27 men; aged 67+/-10 years) with a total of 87 liver metastases from colo-rectal cancer were included in this retrospective analysis. All patients underwent percutaneous RFA after first- or second-line chemotherapy. The mean follow-up period was 29.8 +/- 22.7 (4 - 85) months. Overall survival and local recurrence-free survival were determined using Kaplan-Meier curves. The effects of primary therapeutic success, number of lesions, maximum lesion size and sum of lesion diameters were assessed. RESULTS: In total, 83 lesions were treated during 56 interventions. Taking into account local recurrence and incomplete ablation 86.7 % of metastases were successfully ablated. The median survival was 46 months with estimated 1-, 3- and 5-year survival rates of 89.0 %, 66.2 % and 41.8 %, respectively. The median interval to hepatic tumor progression was 13 months after RFA. Survival was related to primary treatment success (p = 0.0353), number of lesions (p = 0.0050) and sum of lesion diameters (p = 0.0199). CONCLUSION: CT-guided RFA is an effective treatment of liver metastases from colorectal cancer. These data support the use of RFA in patients considered ineligible for surgery.
Subject(s)
Catheter Ablation/methods , Colorectal Neoplasms/pathology , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Aged , Aged, 80 and over , Colorectal Neoplasms/mortality , Disease Progression , Female , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/mortality , Male , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/mortality , Retrospective Studies , Risk Factors , Survival Rate , Tomography, X-Ray ComputedABSTRACT
PURPOSE: To report early results in percutaneous radiofrequency ablation (RFA) of renal cell carcinoma with an expandable RF probe. MATERIAL AND METHODS: In 14 patients (9 male, mean age 67.9 +/- 9.9 years) CT-guided percutaneous radiofrequency ablation of 15 renal cell carcinomas was performed using an expandable LeVeen probe (diameter 2-4 cm) and a 200-watt generator under general anesthesia and CT control. Tumors exceeding a diameter of 3 cm (n=6) were embolized within 24 h prior to RFA. Average tumor size was 3.0 +/- 1.0 cm. RESULTS: RFA was technically successful in all patients, resulting in a mean size of necrosis of 3.7 +/- 0.7 cm. With the exception of one reno-cutaneous fistula, which was successfully treated conservatively, no major complications were observed. No local recurrence was observed (follow-up: 13.9 +/- 12.4 months) while extrarenal tumor progression occurred in four patients. CONCLUSION: Our preliminary data suggest that nephron sparing percutaneous RFA of renal tumors with an expandable RF probe is safe and effective.
